Immuno Oncology Assays Market worth $7.9 billion by 2026
The report "Immuno Oncology Assays Market by Product & Service (Consumables, Instruments, Software), Technology (PCR, NGS, Immunoassay), Cancer Indications (Lung, Breast, Colorectal, Bladder, Melanoma), Application (Research, Diagnostics) - Global Forecast to 2026", is projected to reach USD 7.9 billion by 2026 from USD 4.4 billion in 2021, at a CAGR of 12.5%. The rising incidence of cancer and the growing adoption of targeted therapy drives growth in the immuno-oncology assays market, increased demand for personalized medicine, and the growing significance of companion diagnostics in drug development are among the other factors. Emerging economies such as China and Japan are providing lucrative opportunities for the players operating in the immuno-oncology assays market.
Browse 136 market data Tables and 49 Figures spread through 214 Pages and in-depth TOC on "Immuno Oncology Assays Market by Product & Service (Consumables, Instruments, Software), Technology (PCR, NGS, Immunoassay), Cancer Indications (Lung, Breast, Colorectal, Bladder, Melanoma), Application (Research, Diagnostics) - Global Forecast to 2026 "
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/immuno-oncology-assays-market-52562166.html
The consumables segment accounted for the largest share of the immuno-oncology assays market, by product & service segment, in 2020
Based on product & service, the immuno-oncology assays market is segmented into consumables, instruments, and software & services. The consumables segment accounted for the largest share of the immuno-oncology assays market in 2020. Unlike instruments, consumables require repeat purchase, which results in their stable demand among end users.
NGS segment to register the highest growth rate during the forecast period
The immuno-oncology assays market is segmented into PCR, immunoassay, NGS, flow cytometry, and ISH based on technology. In 2020, the NGS segment accounted for the highest growth rate. Factors such as the launch of new and advanced products, decreased cost of sequencing, presence of advanced NGS technologies, and the increasing incidence of cancer are contributing to the growth of this segment.
The research applications segment accounted for the largest share of the immuno-oncology assays market, by application segment, in 2020
Based on application, the immuno-oncology assays market is segmented into research applications and clinical diagnostics. In 2020, the research applications segment accounted for the largest share of the immuno-oncology assays market. The emergence of cancer immunotherapy is driving this segments growth.
North America is the largest regional market for immuno-oncology assays market
The immuno-oncology assays market is segmented into five regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the immuno-oncology assays market. The large share of this region can be attributed to the increasing healthcare expenditure, highly developed healthcare systems in the US and Canada, and increasing prevalence of cancer.
The major players operating in this market are Thermo Fisher Scientific, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Illumina, Inc. (US), NanoString Technologies, Inc. (US), Sartorius AG (Germany), HTG Molecular Diagnostics, Inc. (US), QIAGEN N.V. (Netherlands), Merck Millipore (US), PerkinElmer, Inc. (US), Abbott Laboratories, Inc. (US), Guardant Health, Inc. (US), bioMérieux SA (France), Myriad Genetics, Inc. (US), MESO SCALE DIAGNOSTICS, LLC. (US), Seegene Inc. (South Korea), Bio-Rad Laboratories, Inc. (US), Charles River Laboratories, Inc. (US), Olink (Sweden), ASURAGEN, INC. (US), Invivoscribe, Inc. (US), Creative Biolabs (US), ReachBio LLC (US), and NMI Technologietransfer GmbH (Germany).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Immuno Oncology Assays Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
